Clinical Trial Update: Leucovorin for the Treatment of 5 q Minus Syndrome [Phase 2]

View source ↗

Summary

This report notes the completion of a Phase 2 clinical trial evaluating leucovorin for 5q minus syndrome, a subset of myelodysplastic syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• 5q Minus Syndrome
• Myelodysplastic Syndrome

Drugs mentioned

• Leucovorin (folinic acid)

Snippet

Sponsor: National Institutes of Health Clinical Center (CC) | Conditions: 5q Minus Syndrome, Myelodysplastic Syndrome | Phase 2 | Status: COMPLETED